correlated with G allele. GG and GT genotypes were higher in CML patients showing imatinib resistance compared to sensitive CML patients (P=0.893, 0.002). Meanwhile TT genotype was shown significantly ... higher among…
region making it a great challenge to the health system. Aims: Since adherence to imatinib contributes to optimal cytogenetic and molecular responses in CML patients, ours. study tries to evaluate ... imatinib adherence…
development of imatinib mesylate (Gleevec, Novartis Pharmaceuticals, Basel, Switzerland) represented a major success for target-directed cancer chemotherapy and a breakthrough in the management of chronic myeloid…
investigate the influences of BST204 extract on the oral absorption and disposition of imatinib, an oral cancer drug, in rats. Rats were orally administered imatinib (30 mg/kg) alone ... BST204 extract (1 g/kg or 0.2…
implicated in many diseases. PDGFRÃ?± is a tyrosine kinase and a side target for imatinib, a revolutionary drug for treatment of chronic myeloid leukaemia (CML) that has dramatically improved ... patients. Given the…
implicated in many diseases. PDGFRÃ?± is a tyrosine kinase and a side target for imatinib, a revolutionary drug for treatment of chronic myeloid leukemia (CML) that has dramatically improved ... patients. Given the…
Imatinib is a highly selective inhibitor of tyrosine kinase used in the treatment of CML and GIST. However, the cost of the drug is prohibitive especially in the developing countries ... this study is to compare…
this research, a fit-for-purpose LC-MS/MS method for quantification of Imatinib Mesylate in rat plasma was developed and utilized for the pharmacokinetic study. Imatinib extraction was done ... isolated from plasma…
leukemia in adults worldwide. At present, the three tyrosine kinase inhibitors (TKI) imatinib, dasatinib, or nilotinib are accepted as the standard first-line treatment in chronic phase (CP). Nilotinib ... second…
anti-oxidant status, micronutrients level in CML patients before and after treatment with imatinib. Methodology: Comparative Study: Fifty (pre-treatment imatinib) patients of CML disease and fifty (post treatment…
protein 2 (SKP2) plays a crucial role in the tumorigenesis of various human cancers. Imatinib, an inhibitor of BCR-ABL tyrosine kinase, c-kit, and platelet derived growth factor receptors ... been investigated. The aim…
Background: The kinase inhibitor, imatinib (Gleevec™, Novartis) has proven to be an effective treatment for chronic myeloid leukemia, providing proof-of-principle for a molecularly targeted approach in oncology. Despite…
first line treatment for CML consists on BCR-ABL inhibitors such as Imatinib. Nevertheless, such treatment may lead to the selection of resistant cells. Hyaluronan (HA) is the main glycosaminoglycan ... that HA induce…
with chronic phase chronic myeloid leukemia (CP-CML) in relation to the duration of Imatinib treatment. Methods: A detailed analysis of 56 adult patients with CP CML divided into groups ... according to the length of…
Background & Aims: The TIDEL II trial indicates first-line imatinib treatment with selective switching to nilotinib for failure to meet specific molecular targets/intolerance, results in excellent molecular responses…
year-old man who was diagnosed with chronic-phase CML and treated with imatinib (400 mg/day) during September 2004 achieved a complete molecular response within 14 months. His liver ... viral hepatitis and autoimmune…
Introduction: The introduction of Imatinib in 1998 has revolutionized the management of chronic myeloid leukemia. Optimal response requires that patients should be maintained on the drug continuously. We retrospectively…
investigate the effect of treatment with resveratrol combined with imatinib mesylate on human chronic myelogenous leukemia K562 cell growth inhibition and apoptosis, in vitro cultured human chronic myelogenous leukemia…
Introduction: Imatinib is approved for the treatment of chronic myeloid leukemia and for gastro intestinal stromal tumors. It is generally well tolerated with mild common toxicities such as diarrhea, fatigue…
Objective and importance: Imatinib–the principle treatment currently available for chronic myeloid leukemia (CML)–may be implicated in neovascular glaucoma (NVG) pathogenesis. Clinical presentation: A 64 year old…
Imatinib side effects related to testicular function have been reported in male patients with chronic myeloid leukemia. These include decreased testosterone levels, gynecomastia and impaired spermatogenesis. To further…
Imatinib is the first-line treatment for Chronic Myeloid Leukemia (CML), it has favorable pharmacokinetic properties, but resistance mechanisms may lead to diminished clinical response over time. Therapeutic Drug…
over time. The objective of the study was to analyze the correlation of imatinib therapy duration and eGFR in CML patients in outpatient clinic of Dr. Soetomo Hospital, Surabaya. This ... observational analytic…
isocratic reverse phase high performance liquid chromatographic (RP-HPLC) method for the estimation of Imatinib in pure and in tablet dosage form. An isocratic RP-HPLC was performed by utilizing ... detection was…
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.